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ABSTRACT
            Over the past decade plants have become an interesting source of new classes of pharmacologically active
natural products. Some secondary metabolites are also well known for their effectiveness on living species. The
PASS (Prediction of Activity Spectra for Substances) computer program, which is able to simultaneously predict
more than one thousand biological and toxicological activities from only the structural formulas of the chemicals,
was used to predict the biological activity profile of 7 secondary metabolites. PASS predictions were successfully
compared to the available information on the pharmacological and toxicological activity of these compounds.
 
INTRODUCTION
             Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the
spread is not controlled, it can result in death. Cancer is caused by both external factors (tobacco, chemicals,
radiation, and infectious organisms) and internal factors (inherited mutations, hormones, immune conditions, and
mutations that occur from metabolism). These causal factors may act together or in sequence to initiate or promote
carcinogenesis. When the control signals in one of the cell goes wrong, and its life cycle becomes disturbed, it
divides and divides. It continues multiplying uncontrollably, and the result of this accumulation of abnormal cells is
a mass of cells called a "tumor". A tumor can be either benign or malignant.
            Benign tumors are non-cancerous and are rarely life-threatening. They do not spread (metastasize) to other
parts of the body. Many breast lumps, for example, are benign tumors.
Malignant tumors are cancerous and can spread to other parts of the body. When a malignant tumor spreads, the
malignant cells break off and travel through the blood lymph system to other places in the body to settle and
multiply; or metastasize, resulting in a new tumor called a secondary tumor, or metastasis. The name given to the
cancer, however, is reflective of the origin of the cancer, even if it has spread to other areas of the body. For
example, if prostate cancer has spread to the liver it is called metastatic prostate cancer.
 Ten or more years often pass between exposure to external factors and detectable cancer. Cancer is treated with
surgery, radiation, chemotherapy, hormone therapy, biological therapy, and targeted therapy. As it is difficult to
differentiate between the cancerous and normal cells in-vivo the innovation of a potential drug against the disease it
yet a menace. With the known therapeutic knowledge and indigenous crude custom scientists have been thriving
their excellence in the field of pharmacology to design a potential drug that is suited to kill the cancerous cells alone.
            Most anti-cancer drugs act by inhibiting DNA synthesis or some other process in the cell growth cycle.
Because anti-cancer drugs generally affect rapidly dividing cells, other non-cancerous cells will also be affected. The
way in which the other cells are affected determines the side-effects of the individual drugs. Other cells affected
include blood cells, which fight infection, help the blood to clot, and carry oxygen to all parts of the body. When
blood cells are affected, patients are more likely to get infections, may bruise or bleed easily, and may feel unusually
weak and very tired. Rapidly dividing cells in hair roots, and cells that line the digestive tract, may also be affected.
As a result, side effects may include loss of hair, poor appetite, nausea and vomiting, diarrhea, or mouth and lip
sores. Many of these side effects can now be controlled, thanks to new or improved drugs. Side effects generally are
short-term and gradually go away. Hair grows back, but it may be different in color and texture. With the known
ethno botanical knowledge and phytochemical interpretations there are a number of drugs that could be effective
against the cancer. The outcome of insilico knowledge on the designing of drug is yet another boom for the
designers to minimize the work, PASS (Prediction of Activity Spectra for Substances) is one such a server that
predicts the possibility of a drug to be active against a target based on the physico- chemical methods using
comparisons and various algorithms.
            PASS predicts simultaneously several hundreds of biological activities (pharmacological main and side
effects, mechanisms of action, mutagenicity, carcinogenicity, teratogenicity and embryotoxicity). The biological
activity spectrum of a compound presents all compounds’ actions despite the difference in essential conditions of its
experimental determination. If the difference in species, sex, age, dose, route, etc. is neglected, the biological activity
can be identified only qualitatively. Thus, "the biological activity spectrum" is defined as the "intrinsic" property of a
compound depending only on its structure and physico-chemical characteristics.
            PASS is the product of ideas originated more than 25 years ago within the framework of the National
Registration System of New Chemical Compounds organized in the USSR in 1972 (Burov et al., 1990). It was
V.Avidon who suggested that many kinds of biological activity could be predicted on the basis of structural formulae
of chemical compounds (Avidon, 1974). Similar approach was under development by V.Golender and A.Rozenblit
(Golender, and Rosenblit, 1983). PASS  has already found new leads with antiulcer, antitumor and antiamnestic
activity, and discovered new mechanism of action for some compounds with known effect (Filimonov and Poroikov,
1996, Filimonov et al., 1995, Poroikov and Staraya Kupavna, 1995, Poroikov et al., 1996, Poroikov et al., 1994).
Experimental determination of drug efficacy and safety is time- and cost-consuming procedure. There exist standard
tests for drug safety assessment (Maggon et. al., 1992) and different strategies for search of new lead compounds
(Walker, 1994). Biological testing is organised taking into account “similarity/dissimilarity” of new compound to the
other known biologically active substances. Several similarity/dissimilarity suggestions are used both in drug design
and screening to determine if particular tests are necessary and sufficient for comprehensive estimation of new
compound activity.  PASS 4.20 training set includes 9314 biologically active substances. PASS 4.20 predicts the
probabilities of presence/absence for 114 biological actions simultaneously (main and side pharmacological effects,
mechanisms, specific toxicity). It is shown that the approach, used in PASS, can be applied to the other biological
activities [Filimonov et al.,1995, Shilova et al.,, Filimonov et al.,1996].In the past years Computer Aided Drug
Design (CADD) is widely used in new drug R & D [Franke and Herrmann, 1994]. Recently, we developed the
computerised system PASS (Prediction of Activity Spectra for Substance) that estimates simultaneously the
probability of more than 100 pharmacological effects and mechanisms [Filimonov et al, 1995, Filimonov and
Poroikov (1996)]. The effectiveness of this computer aided approach application in screening has been shown to be
800% more than the random guess-work [Filimonov and Poroikov (1996)] and 300% more than the estimation by
skilled experts [Poroikov et al., 1993]. However, the antiulcer action has not been covered by the initial version of
PASS. Therefore, in this work we extend PASS prediction’s area on antiulcer activities and use this specialised
system to discover some new antiulcer agents.
            Prediction of this spectrum by PASS is based on SAR analysis of the training set containing more than
35,000 compounds which have more than 500 kinds of biological activity (http://www.ibmh.msk.su/PASS).
Therefore, PASS once trained is able to predict simultaneously all biological activities which are included in the
training set. To provide the best quality of prediction new information about biologically active compounds is
collected permanently from papers and electronic sources and, after the experts' evaluation, is regularly added to the
training set.
MATERIALS AND METHODS
            The following chemical compounds were selected for the study, the predicted structures are obtained from
the Pub-Chem database of National Center for Biotechnology Iinformation.
1. Taxol
Belongs to the family of drugs called mitotic inhibitors. It is obtained via a semi-synthetic process from Taxus
baccata and other species of Taxus (Yew trees). It is approved for treating certain cancers like breast cancer, ovarian
cancer, and lung cancer.
2. Vinblastine
Belongs to the family of plant drugs called vinca alkaloids. It is a mitotic inhibitor. Vinblastine alkaloid is extracted
from Catharanthus roseus. It is used in the treatment for some types of cancer including leukaemia, lymphoma,
breast and lung cancer.
3. Vincristine
Belongs to the family of plant drugs called vinca alkaloids. Vincristine alkaloid is extracted from Catharanthus
roseus, belonging to the family Apocynaceae. This species is also known as Vinca rosea and has the alternative
common name of Vinca. Vincristine is an alkaloid derived from flowering periwinkle. Vincristine is used as a
chemotherapeutic agent for some types of cancers including leukaemia, lymphoma, breast and lung cancer.
4. Topotecan (a camptothecin derivative)
Belongs to the family of drugs called topoisomerase inhibitors. It is also called Hycamtin. Camptothecin, a
quinoline-based alkaloid is isolated from Nothapodytes foetida. It has been approved for ovarian cancer therapy.
5. Irinotecan
Belongs to a family of drugs called topoisomerase inhibitors. It is a camptothecin analog and isolated from
Nothapodytes foetida. Also called CPT 11. It is approved for metastatic colorectal cancers.
6. Etoposide
Belongs to the families of drugs called podophyllotoxin derivatives and topoisomerase inhibitors. Etoposide is a
semisynthetic derivative of the podophyllotoxins, an epipodophyllotoxin. It is used in treating various types of
cancers including bladder cancer, brain tumours, cervical cancer, ependyoma, germ cell tumor and gestational
trophoblastic neoplasia.
7. Teniposide
Belongs to the family of drugs called mitotic inhibitors. Teniposide is a semisynthetic podophyllotoxin derived from
the root of Podophyllum peltatum (the May apple or mandrake). It is used for treating Acute lymphocytic leukemia
and neuroblastoma. 
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            Biological activity is the result of chemical compound's interaction with biological entity. In clinical study
biological entity is represented by human organism. In preclinical testing it is the experimental animals (in vivo) and
experimental models (in vitro). Biological activity depends on peculiarities of compound (structure and physico-
chemical properties), biological entity (species, sex, age, etc.), mode of treatment (dose, route, etc.). Any biologically
active compound reveals wide spectrum of different effects. Some of them are useful in treatment of definite
diseases but the others cause various side and toxic effects. Total complex of activities caused by the compound in
biological entities is called the "biological activity spectrum of the substance".Biological activity spectrum of a
compound presents every its activity despite of the difference in essential conditions of its experimental
determination. The biological activity spectrum of PASS is designed according to the algorithm specified below:
            For the compound under prediction structural descriptors are generated. For each activity the following
values are calculated:
uj = a i ArcSin{ri(2pij-1)}, u0j = a i ArcSin{ri(2pj-1)}
sj = Sin(uj/m), s0j = Sin(u0j/m)
Prj = (1+(sj-s0j)/(1-sjs0j))/2
            Then the results are validated and predicted., In case when the probabilities for more than 400 different
activities are estimated simultaneously, and the ideal training set should include all referenced biologically active
compounds from literature, the best estimate of prediction's quality can be calculated by leave one out cross
validation. Each of the compounds is subsequently removed from the training set and the prediction of its activity
spectrum is carried out on the basis of the remaining part of the training set. The result is compared to the known
activity of a compound, and the maximal error of prediction (MEP) is calculated through the all compounds and
activities.
RESULTS
BIOLOGICAL ACTIVITY SPECTRUM OF THE ANTICANCER DRUGS
TAXOL
76 Substructure descriptors; 0 new.
45 Possible activities at Pa > 30%
Pa Pi for Activity:
0,991   0,001    Antimitotic 
0,982   0,001    Microtubule formation inhibitor 
0,957   0,000    Antimitotic Taxane-like 
0,945   0,001    Microtubule formation stimulant 
0,850   0,004    Protein-arginine deiminase inhibitor 
0,829   0,008    Antineoplastic 
0,707   0,006    Antineoplastic enhancer 
0,691   0,006    Radiosensitizer 
0,652   0,014    CYP2C8 substrate 
0,629   0,022    CYP3A substrate 
0,661   0,106    Phosphatase inhibitor 
0,529   0,001    Beta tubulin antagonist 
 
VINBLASTIN
87 Substructure descriptors; 0 new.
45 Possible activities at Pa > 30%
Pa Pi for Activity:
0,949   0,002    Xenobiotic-transporting ATPase inhibitor 
0,931   0,001    Antineoplastic alkaloid 
0,912   0,003    Lactose synthase inhibitor 
0,896   0,007    Antineoplastic 
0,871   0,001    Tubulin antagonist 
0,870   0,001    Antineoplastic (multiple myeloma) 
0,713   0,027    Teratogen 
0,692   0,007    Cytostatic 
0,659   0,017    Embryotoxic 
0,637   0,029    Toxic 
VINCRISTINE
88 Substructure descriptors; 0 new. 
31 Possible activities at Pa > 30%
Pa Pi for Activity:
0,941   0,001    Antineoplastic alkaloid 
0,917   0,007    Antineoplastic 
0,879   0,001    Tubulin antagonist 
0,853   0,001    Antineoplastic (multiple myeloma) 
0,816   0,003    Leukopoiesis inhibitor 
0,802   0,006    Cytostatic 
0,742   0,021    Teratogen 
0,693   0,014    Embryotoxic 
0,675   0,022    Toxic 
0,579   0,003    Microtubule formation inhibitor 
TOPOTECAN
57 Substructure descriptors; 0 new.
64 Possible activities at Pa > 30%
Pa Pi for Activity:
0,877   0,002    DNA intercalator 
0,870   0,002    Topoisomerase I inhibitor 
0,875   0,007    Antineoplastic 
0,689   0,043    CYP2D16 substrate 
0,626   0,010    Antiviral (Influenza) 
0,614   0,002    Antineoplastic alkaloid 
0,617   0,046    Apoptosis agonist 
0,537   0,082    Magnesium protoporphyrin IX monomethyl ester (oxidative) cyclase inhibitor 
0,523   0,071    Immunomodulator 
0,548   0,107    CYP3A1 substrate 
IRINOTECAN
66 Substructure descriptors; 0 new.
43 Possible activities at Pa > 30%
Pa Pi for Activity:
0,894   0,007    Antineoplastic 
0,840   0,002    DNA intercalator 
0,810   0,002    Topoisomerase I inhibitor 
0,796   0,002    Antineoplastic alkaloid 
0,454   0,035    Antiviral (Influenza) 
0,437   0,047    Alzheimer’s disease treatment 
0,533   0,176    Nerve growth factor agonist 
0,447   0,112    ®-Pantolactone dehydrogenase (flavin) inhibitor 
0,484   0,157    Transplant rejection treatment 
0,359   0,034    Tetrahydroxynaphthalene reductase inhibitor 
ETOPOSIDE
61 Substructure descriptors; 0 new.
72 Possible activities at Pa > 30%
Pa Pi for Activity:
0,976   0,005    Hematotoxic 
0,930   0,007    Antineoplastic 
0,907   0,000    Antimitotic Podophyllotoxin-like 
0,819   0,012    Pulmonary hypertension treatment 
0,803   0,003    Topoisomerase I inhibitor 
0,756   0,006    Carcinogenic, group 2A 
0,725   0,008    CYP3A5 substrate 
0,696   0,015    Emetic 
0,683   0,003    DNA intercalator 
0,666   0,002    Antimitotic 
TENIPOSIDE
67 Substructure descriptors; 0 new.
63 Possible activities at Pa > 30%
Pa Pi for Activity:
0,942   0,006    Antineoplastic 
0,902   0,004    Xenobiotic-transporting ATPase inhibitor 
0,823   0,010    Cardiotoxic 
0,782   0,016    Pulmonary hypertension treatment 
0,726   0,004    Topoisomerase I inhibitor 
0,717   0,007    Carcinogenic, group 2A 
0,657   0,013    CYP2B6 substrate 
0,606   0,012    CYP3A5 substrate 
0,610   0,017    Beta-amylase inhibitor 
0,598   0,027    Emetic 
 
DISCUSSION
            Pa and Pi are the estimates of probability for the compound to be active and inactive respectively for each
type of activity from the biological activity spectrum. Their values vary from 0.000 to 1.000. It is reasonably that
only those types of activities may be revealed by the compound, which Pa > Pi and so they are put into the
biological activity spectrum.
            Planning experiments and choosing the activities on which the compound has to be tested, one should have
in mind the necessity of balancing between the novelty of pharmacological action and the risk to obtain negative
result in experimental testing. Certainly, one will also take into account the particular interest in some kinds of
activity, experimental facilities, etc.
The accuracy of prediction is about 90%.
 
CONCLUSION
            All the seven drugs estimated show a good tendency to fight against the neoplastic cancer, also the drug
Irinotecan is against Alzimers disease. Teniposide is not as worthy as others as it is a cardiotoxic. Topotecan,
Etaposide and Irinotecan are DNA intercalators. Now a bandwith of drugs for the cancer treatment is analysed,it
must be improved and lot of studies have to be continued to ensure its activity invitro and invivo.
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